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OBJECTIVEdTo identify if there is a dose-dependent risk of diabetes complications in
patients treated with corticosteroids who have both diabetes and chronic obstructive pulmonary
disorder (COPD).
RESEARCH DESIGNANDMETHODSdA retrospective study of administrative claims
data from the Australian Government Department of Veterans’ Affairs, from 1 July 2001 to 30
June 2008, of diabetes patients newly initiated on metformin or sulfonylurea. COPD was iden-
tiﬁed by dispensings of tiotropium or ipratropium in the 6 months preceding study entry. Total
corticosteroid use (inhaled and systemic) in the 12months after study entry was determined. The
outcome was time to hospitalization for a diabetes-related complication. Competing risks and
Cox proportional hazard regression analyses were conducted with adjustment for a number of
covariates.
RESULTSdA total of 18,226 subjects with diabetes were identiﬁed, of which 5.9%had COPD.
Of those with COPD, 67.2% were dispensed corticosteroids in the 12 months from study entry.
Stratiﬁcation by dose of corticosteroids demonstrated a 94% increased likelihood of hospitali-
zation for a diabetes complication for those who received a total deﬁned daily dose (DDD) of
corticosteroids$0.83/day (subhazard ratio 1.94 [95%CI 1.14–3.28], P = 0.014), by comparison
with those who did not receive a corticosteroid. Lower doses of corticosteroid (,0.83 DDD/day)
were not associated with an increased risk of diabetes-related hospitalization.
CONCLUSIONSdIn patients with diabetes and COPD, an increased risk of diabetes-related
hospitalizations was only evident with use of high doses of corticosteroids. This highlights the
need for constant revision of corticosteroid dose in those with diabetes and COPD, to ensure that
the minimally effective dose is used, together with review of appropriate response to therapy.
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The presence of comorbidity in olderpeople with diabetes is common, atleast 50% will have three or more
comorbid chronic conditions (1,2). Co-
morbidity adds considerable complexity
to therapeutic management (2) and is a
major determinant of functional capabil-
ities and health outcomes (3,4). Chronic
obstructive pulmonary disorder (COPD)
is a common comorbidity; ;10% of pa-
tients with diabetes will have COPD (1,2).
COPD is a progressive, largely nonrevers-
ible pulmonary disease that is a major
cause of morbidity and mortality world-
wide (5). COPD is associated with in-
creased complexity of care in those with
diabetes, potentially the result of a reduced
ability to perform self-management ac-
tivities necessary for optimal diabetes
control and the associated therapeutic
challenges (6).
Current guideline treatment recom-
mendations for COPD include the use of
inhaled corticosteroids to reduce exacer-
bations and improve health status in
patients with moderate to severe COPD
who have frequent exacerbations (7,8).
Oral corticosteroids are also recommen-
ded for the short-term treatment of exac-
erbations to improve lung function and
hypoxemia and to reduce recovery time,
but are not recommended chronically
due to their unfavorable risk/beneﬁt
proﬁle (7,8). Corticosteroids are not
recommended in patients with diabetes
(9) due to a dose-dependent increase
in blood glucose levels with corticoste-
roid use and increased risk of diabetes
progression (10,11). There is little evidence-
based information to facilitate the treat-
ment of patients with both diabetes and
COPD, where optimal treatment of
COPD with corticosteroids may result
in a potentially increased risk of diabetes
complications and poorer health out-
comes. This study aimed to examine the
dose-dependent risk of diabetes-related
complications associated with corticoste-




Data source and study design
This study was approved by the Univer-
sity of South Australia and the Australian
Government Department of Veterans’ Af-
fairs (DVA) Human Research Ethics Com-
mittees. A retrospective cohort study was
undertaken from 1 July 2001 to 30 June
2008 using data from the DVA health ad-
ministrative claims database. The DVA
database contains details of all prescrip-
tion medicines and medical and allied
health services and hospitalizations sub-
sidized by DVA for a treatment popula-
tion of 290,000 veterans, war widows,
and widowers. Over 70% of the popula-
tion are 70 years of age or older; 54% are
male and 9.8% live in residential aged
care, and they are dispensed an average
of 11 unique medicines annually (12).
Within the dataset, medicines are coded
according to the World Health Organiza-
tion (WHO) anatomical and therapeutic
chemical (ATC) classiﬁcation (13) and the
Schedule of Pharmaceutical Beneﬁts item
codes (14). Hospitalizations are coded
according to the WHO Australian modi-
ﬁcation of the ICD-10 (ICD-10-AM) clas-
siﬁcation (15).
Cohort selection
Subjects were included if they were eligi-
ble for all health services subsidized by
DVA in the 12 months prior to the date
of their ﬁrst (index) dispensing of an
oral antidiabetic medicine. The study
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included new users of either metformin or
sulfonylurea medicines, deﬁned by those
who did not have a dispensing of these
medicines in the 12 months prior. Users
of other classes of diabetes medicines
(insulin, other oral medications, and
combination of metformin) were ex-
cluded, as prescription of these medicines
at the initiation of diabetes treatment is
not recommended as ﬁrst-line pharmaco-
therapy and may relate to unusual clinical
circumstances (16). Newly initiated med-
icine users were selected for study as these
patients are less likely to have existing
complications than those who are on
second- and third-line agents (insulin or
other oral medications) (16). Comorbid
COPD was identiﬁed from medicine use,
deﬁned as two dispensings of tiotropium
or ipratropium (ATC codes R03BB04 and
R03BB01, respectively) in the 6 months
preceding the ﬁrst dispensing of the oral
antidiabetic medicine. Figure 1 shows the
ﬂowchart of the study cohort selection
criteria.
Calculation of corticosteroid dose
The total cumulative corticosteroid dose
(both inhaled and systemic [oral], ATC
codes R01AD-R03BA and H02AB01-
AB10, respectively) was calculated in the
12months from study entry and converted
to a deﬁned daily dose (DDD) per day
(17). In order to account for the systemic
bioavailability of inhaled corticosteroids
by comparison with that of oral cortico-
steroids, the WHO-deﬁned dose of in-
haled corticosteroids was reduced by a
factor of 10 (18). Users of corticosteroids
were stratiﬁed into three groups: .0 to
,0.25, $0.25 to ,0.83, and $0.83
DDD/day.
Outcome deﬁnition
The study end point was time until ﬁrst
hospitalization for a diabetes-related
complication, deﬁned by the ICD-10-
AM codes E11 and E13–E14 (15). These
include diabetic hyperosmolarity with or
without coma, diabetic ketoacidosis with
or without coma, diabetic nephropathy,
diabetic retinopathy, diabetic neuropa-
thy, diabetic angiopathy, and diabetic ar-
thropathy. Follow-up commenced 12
months from index dispensing of antidia-
betes medicine. Participants were cen-
sored at death or study end.
Statistical analyses
We used an intention-to-treat approach
to compare risk of diabetes complications
between users and nonusers of cortico-
steroids in our diabetes and COPD cohort.
These analyses assessed the effect of treat-
ment in the ﬁrst 12 months from incident
antidiabetes medicine use. Characteristics
of nonusers and users of corticosteroids
were compared using a Mann-Whitney
U test for continuous variables and x2 test
for categorical variables. As death is a
competing risk event in this elderly study
population that may preclude the onset
of the outcome of interest (time to hospi-
talization for a diabetes-related compli-
cation), we calculated the cumulative
incidence of outcome of interest in the
presence of competing risk events. Com-
peting risk regression analyses were con-
ducted using the Fine and Gray approach,
which extends the Cox model to compet-
ing risks data by considering the subdis-
tribution hazard (19). The strength of the
association between each variable and the
outcome was assessed using the subhaz-
ard ratio (SHR), which is the ratio of haz-
ards associated with the cumulative
incidence function under different values
of the covariates. Covariates included age,
sex, socioeconomic status (20), residential
status (community dwelling or aged-care
resident), number of comorbid conditions
(identiﬁed using the pharmaceutical-
based comorbidity index, Rx-Risk-V
[21], excluding those conditions used to
identify patients), number of prescribers,
number of unique medicines (excluding
those medicines used to identify pa-
tients), number of visits to an endocrinol-
ogist, number of visits to a pulmonary
specialist, number of hospitalizations for
conditions other than diabetes, exposure
to corticosteroids in the 12 months prior
to study entry, and glycated hemoglobin
(HbA1c) testing in the 12 months prior to
study entry. All covariates were time vary-
ing, adjusted at study entry and then an-
nually, apart from age, socioeconomic
status, prior corticosteroid exposure,
and HbA1c testing, which were adjusted
at baseline only. The subproportional
hazards assumption was conﬁrmed by ex-
amining log[2log(survival)] curves, and
no violation was detected. We also exam-
ined cause-speciﬁc Cox proportional haz-
ard models, with death censored and
adjusting for the same covariates as in-
cluded in the competing risks regression
analyses, to provide a more complete un-
derstanding of the association between
corticosteroid use and time until diabetes
complication (22). Statistical analyses
were performed using SAS 9.2 and Stata
11.0.
RESULTSdA total of 1,077 (5.9%) of
the 18,226 patients with diabetes had
comorbid COPD. In the 12 months after
study entry, corticosteroids were used by
724 (67.2%) of those with diabetes and
COPD. For those who received a cortico-
steroid, the median corticosteroid dose
over the 12-month period was 0.34 DDD/
day (IQR 0.11–0.83). The characteristics
of the study cohort at study entry are de-
scribed in Table 1. Those who were users
of corticosteroids had a statistically signif-
icant greater number of comorbid condi-
tions and hospitalizations and were more
likely to visit an endocrinologist or pul-
monary specialist.
After 1 year, there was little difference
between the proportion of those who
had a hospitalization for a diabetes com-
plication between nonusers (6.3% [95%
CI 4.01–9.63]) and users (7.1% [5.29–
9.16]) of corticosteroids (P = 0.37; data
not shown). After 5 years of follow-up,
19.8% (18.72–23.45) of corticosteroid
users had a diabetes-related hospitaliza-
tion, by comparison with 16.2% (16.91–
22.84) for nonusers of corticosteroids
(P = 0.18).
Shown in Fig. 2 is the dose-dependent
analysis of corticosteroid use and time to
hospitalization for a diabetes complica-
tion. Stratiﬁcation of corticosteroid dose
demonstrated that a total dose of $0.83
DDD/day, over the 12 months from study
Figure 1dStudy ﬂowchart of diabetes and
COPD cohort selection.
3010 DIABETES CARE, VOLUME 36, OCTOBER 2013 care.diabetesjournals.org
Corticosteroids and diabetes complications
entry, resulted in a 94% increased risk of
diabetes complication (SHR 1.94 [95% CI
1.14–3.28], P = 0.014) by comparison
with those who did not receive a cortico-
steroid (Table 2). Despite observing a
dose-dependent increase in risk, this was
not statistically signiﬁcant for the lower
two corticosteroid dose treatment groups
(Table 2). Hazard ratios (HRs) for both the
lower two doses of corticosteroids using
competing risk or Cox proportional haz-
ards regression analyses were similar. The
HR for the higher-dose grouping of corti-
costeroid $0.83 using Cox proportional
hazards regression analysis demonstrated
an increased risk (HR 2.46 [95% CI 1.45–
4.18], P = 0.001) by comparison with
competing risk (SHR 1.94 [1.14–3.28],
P = 0.014), highlighting the increasing in-
ﬂuence of the competing risk of death, for
this dose.
We examined the risk of diabetes
hospitalizations in those who received
inhaled only, oral only, and both. Inhaled
corticosteroid only was received by
24.8%, with a median total dose of 0.08
DDD/day (IQR 0.03–0.13); 46.5% re-
ceived an oral corticosteroid only, with a
median total dose of 0.49 DDD /day (IQR
0.21–0.99); and 28.7% received both an
inhaled and oral corticosteroid with a me-
dian total dose of 0.64 DDD/day (IQR
0.07–3.04) (Table 3). Competing risk
analysis stratiﬁed by corticosteroid use
(inhaled, oral, and both) showed no sig-
niﬁcant association between corticoste-
roid use and risk of a diabetes-related
hospitalization (Table 3).
CONCLUSIONSdIn this large
population-based study of older people
with COPD and diabetes, a dose of corti-
costeroids of $0.83 DDD/day in the 12
months after starting diabetes medication
was associated with a 94% increased risk
of having a hospitalization for a diabetes
complication. This increased risk was not
evident for doses,0.83 DDD/day. To our
Table 1dDemographic and clinical characteristics of study cohort (n = 1,077)
Diabetes and COPD
(n = 353)
Diabetes and COPD + corticosteroids
(n = 724) P valuea
Age (years) (median, IQR) 80.2 (75.3–83.1) 79.7 (75.8–82.7) 0.10
Sex (% male) 70.9 71.0 0.97
Residential status (% RAC) 4.4 4.8 0.93
Socioeconomic index of disadvantage 0.59
Lowest disadvantage (%) 20.1 20.3
Medium ⁄ low disadvantage (%) 24.8 22.4
Medium ⁄ high disadvantage (%) 27.7 30.9
Highest disadvantage (%) 27.4 26.4
Number of comorbid conditionsb (median, IQR) 6 (4–8) 7 (5–9) ,0.001
Number of unique medicinesb (median, IQR) 5 (3–9) 7 (4–11) ,0.001
Number of prescribersb (median, IQR) 2 (1–3) 2 (1–4) 0.05
Number hospitalizationsb (median, IQR) 1 (0–2) 1 (0–3) 0.014
Use of medicines indicative of cardiovascular
disease/hypertensionc (%) 92.5 94.0 0.43
Corticosteroid used (%) 40.1 86.8 ,0.001
Number of corticosteroid prescriptionsc (median, IQR) 1 (0–2) 6 (2–11) ,0.001
HbA1c test
d 25.3 23.3 0.49
Number of HbA1c tests
c (mean, SD) 0.48 (0.77) 0.33 (0.69) 0.013
Number hospitalizations in 12 months after study entryc
(median, IQR) 1 (0–3) 2 (0–4) 0.001
Endocrinologist visitd (%) 5.9 9.4 0.028
Pulmonary specialist visitd (%) 24.2 34.4 ,0.001
RAC, residential aged care. aBy comparison with those with diabetes and COPD who were not dispensed corticosteroids in the 12 months after index date. bDe-
termined in 6 months prior to study entry. cIncluded C02, antihypertensives; C03, diuretics; C07, b-blockers; C08, calcium channel blockers; C09, agents acting on
the renin-angiotensin system; C10, lipid-modifying agents. dDetermined in the 12 months after study entry.
Figure 2dCumulative incidence of time to hospitalization for a diabetes complication stratiﬁed
by total cumulative dose (DDD) of corticosteroids in the 12 months from study entry.
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knowledge, this is the ﬁrst study to have
examined the effect of corticosteroid dose
on longer-term diabetes complications for
patients with diabetes and comorbid
COPD. Older patients and those with a
comorbidity are generally excluded from
randomized clinical trials used to gener-
ate the evidence for clinical guidelines,
decreasing the applicability of trial results
to real-world populations (23). The re-
sults of this study suggest that, when
they are necessary to use, corticosteroids
should be used in their minimally effec-
tive dose for older patients with diabetes
and COPD.
The use of inhaled corticosteroids for
patients with COPD has been the subject
of much debate (5). Inhaled corticoste-
roids have been shown to reduce the fre-
quency of exacerbations and decline in
quality of life in people with COPD but
have no effect on the rate of decline in
lung function or mortality (5). Although
they are recommended for use in those
with moderate to severe COPD, inhaled
corticosteroids are used widely, with
reports of use in .70% of patients with
COPD (24).
Whereas systemic corticosteroids are
known to increase diabetes risk (25), the
effects of inhaled corticosteroids are less
well known. In a recent large population–
based study of 388,584 patients with re-
spiratory disease, treatment with inhaled
corticosteroids was associated with a 34%
(RR 1.34 [95% CI 1.29–1.39]) increased
risk of diabetes onset (deﬁned by com-
mencement of an oral hypoglycemic
agent), with the highest dose associated
with the greatest risk (11). Furthermore,
in a subset of patients with respiratory
disease and newly diagnosed diabetes
treated with oral hypoglycemic agents, in-
haled corticosteroid use was associated
with a 34% (RR 1.34 [1.17–1.53]) in-
creased likelihood of progression to insu-
lin use, with higher doses associated
with a 54% increased risk (11). This dem-
onstrates the short-term systemic effects
of inhaled corticosteroid use, resulting in
hyperglycemia and the subsequent need
for the use of oral antidiabetic agents or
intensiﬁcation of treatment. We stratiﬁed
our analyses by type of corticosteroid dis-
pensed (inhaled, oral, or those who re-
ceived both) and found no signiﬁcant
association with risk of diabetes-related
hospitalization. However, the median
doses of each of these groups were lower
than $0.83 DDD/day, consistent with
our results, where an association of in-
creased risk of diabetes-related hospitali-
zation was only observed at these higher
doses.
Previous studies have shown that
corticosteroids are associated with insu-
lin resistance, hyperglycemia, and loss of
diabetic control in a dose-dependent
manner in patients with diabetes
(10,25). Corticosteroids have been
shown to inhibit a number of steps in
the insulin signaling network, leading
to insulin resistance. These include in-
creased proteolysis, lipolysis, and free
fatty acid production, which can contrib-
ute to insulin resistance. Corticosteroids
can also directly increase hepatic gluco-
neogenesis, leading to hyperglycemia
(26). The results of the current study
provide an insight into potential safety
concerns of corticosteroid use in a real-
world setting for the treatment of COPD
in patients with comorbid diabetes,
where both oral and systemic corticoste-
roids are used. This highlights the poten-
tial for longer-term adverse effects of
higher doses of both oral and systemic
corticosteroids on diabetes complica-
tions in older patients with diabetes and
COPD.
Diabetes and COPD are common
comorbid disorders, and both the preva-
lence and incidence of type 2 diabetes are
higher in patients with COPD, by com-
parison with those without COPD
(27,28). The presence of comorbidity
adds considerable complexity to the ther-
apeutic management, with .60% of
those with diabetes having a comorbid
condition that may cause a treatment con-
ﬂict, affecting both the beneﬁts and risks
associated with treatment choices (2). The
presence of both diabetes and COPD has
been reported to be associated with
greater care complexity (6). Greater num-
bers of comorbid conditions or the pres-
ence of comorbid cardiovascular disease,
hypertension, anxiety, or depression are
associated with increased respiratory im-
pairment and risk of hospitalization and
mortality (5,28). Our results highlight the
importance of the need for shared deci-
sion making in this population, where
treatment prioritization of the more
Table 2dCompeting risk and Cox proportional hazards regression analyses for time to
hospitalization for diabetes complication, stratiﬁed by total dose (DDD) of corticosteroid/day
in the 12 months from study entrya
Competing risk Cox proportional hazards
SHR 95% CI P value HR 95% CI P value
Reference, no corticosteroids
(n = 353)
DDD .0 to ,0.25 (n = 358) 1.13 0.72–1.79 0.59 1.09 0.69–1.73 0.69
DDD $0.25 to ,0.83 (n = 154) 1.58 0.96–2.59 0.07 1.63 0.99–2.67 0.052
DDD $0.83 (n = 212) 1.94 1.14–3.28 0.014 2.46 1.45–4.18 0.001
SHR is from multivariable competing risk regression analyses. HR is from Cox proportional hazards re-
gression analyses. aAdjusted for age, sex, socioeconomic status, residential status, number of comorbid
conditions, number of prescribers, number of unique medicines, number of visits to an endocrinologist,
number of visits to a pulmonary specialist, number of hospitalizations, prior exposure to corticosteroids, and
HbA1c testing in 12 months prior to study entry.
Table 3dCompeting risk regression analyses for time to hospitalization for diabetes
complication, stratiﬁed by inhaled corticosteroids, oral corticosteroids, or botha
Competing risk
Median dose DDD/day (IQR) SHR 95% CI P value
Reference, no corticosteroids
(n = 353)
Inhaled only (n = 179) 0.08 (0.03–0.13) 0.92 0.54–1.56 0.74
Oral only (n = 337) 0.49 (0.21–0.99) 1.22 0.69–1.84 0.48
Inhaled and oral (n = 208) 0.64 (0.26–1.03) 1.42 0.93–2.18 0.11
SHR is from multivariable competing risk regression analyses. aAdjusted for age, sex, socioeconomic status,
residential status, number of comorbid conditions, number of prescribers, number of unique medicines,
number of visits to an endocrinologist, number of visits to a pulmonary specialist, number of hospitalizations,
prior exposure to corticosteroids, and HbA1c testing in 12 months prior to study entry.
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symptomatic conditions, such as COPD,
needs to be balanced with both the short-
term and long-term harms associated
with use of corticosteroids for patients
with comorbid diabetes. Although we
have shown that longer-term adverse ef-
fects on diabetes complications were only
evident at higher doses of corticosteroids,
use of corticosteroids (both inhaled and
oral) in this patient population should be
associated with close monitoring of blood
glucose levels and a review of efﬁcacy
within 4–8 weeks of commencing inhaled
therapy. Regular use of high-dose cortico-
steroids should be avoided where possible
($0.83 DDD/day) for those individuals
with comorbid diabetes.
Our study has a number of limita-
tions. The identiﬁcation of patients with
COPD in our study was based on dis-
pensings of either- the short or long-
acting anticholinergic agent ipratropium
or tiotropium, respectively. We have not
included patients who are only taking b-2
agonists as these drugs may also be used
for asthma or in those with mild or newly
diagnosed COPD, and as such, we may
have excluded patients with less severe
COPD in our study. A recent Australian
study of patients with COPD showed
that the majority (89%) used tiotropium
or ipratropium as their regular COPD
therapy (29). The use of an intention-to-
treat analysis may have resulted inmisclas-
siﬁcation of corticosteroid exposure dur-
ing follow-up; however, the median dose
of corticosteroids within the second year
after study entry was 0.27 DDD/day (IQR
0.09–0.66), similar to that of the ﬁrst
12 months, suggesting that this was
minimized.
Although we included a number of
covariates in our analyses to adjust for
several potential confounders, residual
confounding from unmeasured covari-
ates may still exist. The issue of con-
founding by indication also deserves
consideration; those with more severe
COPD are more likely to receive a corti-
costeroid, which may be associated with
the outcome of a diabetes-related hospi-
talization. Despite a lack of evidence to
support that severity of COPD is on the
causal pathway to an increased likelihood
of a diabetes-related hospitalization, there
is, however, the potential that a nonbio-
logical causal bias exists; that is, compet-
ing priorities, whereby those who have
more severe COPDmay have less capacity
to focus on management of their comor-
bid diabetes and therefore have poorer
diabetic control. A number of covariates
were included in our analyses as a proxy
for COPD disease severity, including
number of unique medicines (which in-
cluded b-agonists and antibiotics), num-
ber of visits to a pulmonary specialist, and
number of hospitalizations (including
those that are COPD related). We also ad-
justed for potential differences in diabetes
severity at study entry due to prior corti-
costeroid exposure in our analyses.
Our study end point mainly included
microvascular diabetes complications
and did not include macro/cardiovascular
complications, as almost all of the study
population (.92%) had pre-existing car-
diovascular comorbidity at study entry.
The results of the current study are likely
to be applicable to the older Australian
population; age-speciﬁc comparisons of
DVA gold card holders with no service-
related disability with the wider Austra-
lian population have shown similar rates
of general practitioner visits, use of pre-
scriptions, and hospitalizations (30).
In conclusion, use of a higher dose of
corticosteroids is associated with an in-
creased risk of diabetes complications in
diabetes patients with comorbid COPD.
Use of corticosteroids in patients with
diabetes and COPD should be accompa-
nied by regular review to ensure that
minimally effective doses are used, efﬁ-
cacy of treatment, and close monitoring
of blood glucose control. Treatment with
higher doses of corticosteroids in pa-
tients with diabetes and COPD should
be limited to optimize the balance be-
tween risk of beneﬁts and longer-term
adverse effects.
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